

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Thomas L. CANTOR et al.

Patent No.: 7,459,276

Issued: December 2, 2008

For: METHODS AND CONTROLS FOR
MONITORING ASSAY QUALITY AND
ACCURACY IN PARATHYROID HORMONE
MEASUREMENT

**REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.322**

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In the Specification:

Column 1, line 67, "under tang" should read --undertaking--.

Column 3, line 62, "acridities" should read --acridinium--.

Column 6, line 27, "FM" should read --PTH--.

Column 6, line 29, "an analyze for which an analyze" should read --an analyte for which an analyte--.

Column 6, line 65, "pmolmL" should read --pmol/mL--.

Column 7, line 51, "biotherapy" should read --mistherapy--.

Column 7, line 65, "analyses" should read --analytes--.

Column 8, line 10, ""analyze of interest" refers to the analyze" should read --"analyte of interest" refers to the analyte-- .

Column 8, line 12, "legend" should read --ligand--.

Column 8, line 13, "legend" should read --ligand--.
Column 8, line 16, ""legend binding partner" refers to a legend" should read --"ligand binding partner" refers to a ligand--.
Column 8, line 17, "legend" should read --ligand--.
Column 8, line 18, "legend" should read --ligand--.
Column 8, line 19, "legend" should read --ligand--.
Column 8, line 20, "legend" should read --ligand--.
Column 8, line 21, "legend" should read --ligand--.
Column 8, line 22, "legend" should read --ligand--.
Column 8, line 24, "legend" should read --ligand--.
Column 8, line 26, "legend" should read --ligand--.
Column 8, line 28, "legend" should read --ligand--.
Column 8, line 29, ""legend binding partner," while the signal legend" should read --"ligand biding partner," while the signal ligand--.
Column 8, line 31, "legend" should read --ligand--.
Column 8, line 32, "legend for binding to a particular legend" should read --ligand for binding to a particular ligand--.
Column 8, line 37, "legend" should read --ligand--.
Column 8, line 41, "legend binding partner and a target legend" should read --ligand binding partner and a target ligand--.
Column 10, line 8, "Amstein" should read --Arnstein--.
Column 14, line 66, "hemolytic" should read --hemolysis--.
Column 14, line 67, "immunologic" should read --immunoglobulin--.
Column 15, line 29, "acridities" should read --acridinium--.

The errors were not in the application as filed by applicant; accordingly no fee is required.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment.
Patentee respectfully solicits the granting of the requested Certificate of Correction.

Dated: April 29, 2009

Respectfully submitted,

Electronic signature: /Michael G. Smith/
Michael G. Smith

Registration No.: 44,422
MORRISON & FOERSTER LLP
12531 High Bluff Drive, Suite 100
San Diego, California 92130-2040
(858) 720-5113